As many as __ of patients treated with a biologic disease-modifying antirheumatic drug experience a suboptimal response either initially or over time.(1)
C.) As many as 40% of patients treated with a TNF inhibitor experience a suboptimal response either initially or over time.(1) Schwartz DM, Kanno Y, Villarino A, Ward M, Gadina M, O'Shea JJ. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017;16(12):843-862.
Click the ‘Continue’ button to learn about approved and emerging JAK inhibitor treatment options that may help RA patients achieve and sustain complete remissions.
Elena M. Massarotti, MD
Associate Professor of Medicine
Harvard Medical School
Director of Clinical Lupus Trials, Division of Rheumatology
Vice Chair of Clinical Affairs, Department of Medicine
Brigham and Women's Hospital
William F.C. Rigby, MD
Vice Chairman, Academic Affairs
Department of Medicine
Professor of Medicine, Microbiology, and Immunology
Director, Rheumatology Research
Dartmouth Geisel School of Medicine
Amy Burdette, PhD
Manager, Educational Strategy & Content
Rebecca L. Julian, MS, ELS
Senior Manager, Editorial
Kathryn Schaefer, MSN, RN, CPHRM
Senior Manager, Accreditation and Compliance
East Lansing, MI
Upon completion, participants should be able to:
- Describe the clinical rationale for the modulation of JAK signaling as a therapeutic target in RA
- Apply information about the anticipated agent-specific clinical properties of various JAK inhibitors to individualized treatment decisions as these therapies become available
This activity is intended for rheumatologists.
Statement of Need
Despite a broad selection of approved treatments for rheumatoid arthritis (RA), most patients with this condition do not experience a complete, long-term response with currently available therapies. In an effort to more consistently achieve and sustain complete remissions, ongoing investigation has shifted focus to intracellular mediators of inflammation, such as the JAK family—a leading target of over 50 cytokines used in the JAK pathway to transduce intracellular signals. As such, targeting the JAK family is a rational therapeutic approach with potentially broad applications. Agents that have a broad JAK inhibition are now available for patients with RA, and the safety profiles of these treatments are largely predictable based on the biological functions of the targeted JAK isoforms. Novel agents with narrow JAK inhibition are also being investigated to address unmet treatment needs for this patient population. Soon clinicians may have additional JAK inhibitors in the RA armamentarium to select among when developing individualized treatment plans for patients with RA.
Provided by Med-IQ.
Med-IQ is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Med-IQ designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurse practitioners, physician assistants, and other healthcare professionals who successfully complete the activity will receive a Statement of Participation indicating the maximum credits available.
Medium/Method of Participation
This CME activity consists of a 1.0-credit online publication. To receive credit, read the introductory CME material, read the publication, and complete the post-survey, evaluation, attestation, and post-test, answering at least 70% of the post-test questions correctly.
Initial Release Date: December 17, 2018
Expiration Date: December 16, 2019
Estimated Time to Complete This Activity: 1 hour
Med-IQ requires any person in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as those in any amount occurring within the past 12 months, including those of a spouse/life partner, that could create a conflict of interest (COI). Individuals who refuse to disclose will not be permitted to contribute to this CME activity in any way. Med-IQ has policies in place that will identify and resolve COIs prior to this educational activity. Med-IQ also requires faculty to disclose discussions of investigational products or unlabeled/unapproved uses of drugs or devices regulated by the US Food and Drug Administration.
The content of this activity has been peer reviewed and has been approved for compliance. The faculty and contributors have indicated the following financial relationships, which have been resolved through an established COI resolution process, and have stated that these reported relationships will not have any impact on their ability to give an unbiased presentation.
Elena M. Massarotti, MD
Consulting fees/advisory boards: Regeneron Pharmaceuticals, Inc., Sanofi-aventis U.S. Inc.
Contracted research: Sanofi-aventis U.S. Inc.
William F.C. Rigby, MD
Consulting fees/advisory boards: AbbVie, Inc., Bristol Myers-Squibb, F. Hoffman La-Roche, Pfizer, Inc.
Fees received for promotional/non-CME activities: Bristol Myers-Squibb
The writer, peer reviewers, and activity planners have no financial relationships to disclose.
Statement of Evidence-Based Content
Educational activities that assist physicians in carrying out their professional responsibilities more effectively and efficiently are consistent with the ACCME definition of continuing medical education (CME). As an ACCME-accredited provider of CME, it is the policy of Med-IQ to review and ensure that all the content and any recommendations, treatments, and manners of practicing medicine in CME activities are scientifically based, valid, and relevant to the practice of medicine. Med-IQ is responsible for validating the content of the CME activities it provides. Specifically, (1) all recommendations addressing the medical care of patients must be based on evidence that is scientifically sound and recognized as such within the profession; (2) all scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to generally accepted standards of experimental design, data collection, and analysis.
Med-IQ is not liable for any decision made or action taken in reliance upon the information provided through this activity.
For questions or comments about this activity, please contact Med-IQ. Call (toll-free) 866 858 7434 or email firstname.lastname@example.org.
Operating system - Med-IQ supports the following operating systems:
- Microsoft Windows supported by Microsoft
- Mac OS supported by Apple
Browsers - Med-IQ supports the current version of each browser listed below, plus two prior versions:
Microsoft Internet Explorer
- Microsoft Edge
Operating system - Med-IQ supports the current operating system, plus two prior releases:
- Android (eg, Samsung Galaxy)
- Apple (eg, iPhone/iPad)
Browsers - Med-IQ supports the default browser for the applicable operating system release, plus two prior releases:
- Android (Chrome)
- Apple (Safari)
Applications & Software
PDF Viewer - Adobe Acrobat Reader or Adobe Reader
Adobe Flash Player - Med-IQ supports the current version, plus two prior versions
For technical assistance, please refer to our Support Manual.
Med-IQ fully complies with the legal requirements of the ADA and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please contact Med-IQ at 443 543 5200.
The information provided through this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.
Privacy & Confidentiality
Acknowledgment of Commercial Support
This activity is supported by an educational grant from Gilead Sciences.
© 2018 Med-IQ, Inc.
Unless otherwise indicated, photographed subjects who appear within the content of this activity or on artwork associated with this activity are models; they are not actual patients or doctors.